# Sermorelin References: The Cited GHRH(1-29) Literature

> Sermorelin references — the full cited literature behind this digest, with DOIs, PubMed links, and trial registrations for every quantitative claim about GHRH(1-29) and its analogs.

Every quantitative claim on this site maps to one of these studies. DOIs, PubMed identifiers, and trial registrations included.

## How to read this list

These are the **sermorelin** and GHRH-analog sources cited throughout this digest. Each numbered entry corresponds to the inline [N] markers on the other pages, and each carries a DOI or PubMed identifier so any claim can be traced to its source. The list spans the pediatric efficacy trial, the older-men GH/IGF-1 study, the pharmacokinetic work, the cognition trials of a GHRH analog, the mechanism and feedback reviews, and the recent GHRH-analogue syntheses. Where a finding comes from the related analog tesamorelin rather than native sermorelin, the body text says so; this index lists the underlying study.

## References

[1] Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. J Clin Endocrinol Metab. 1996;81(3):1189-96. https://pubmed.ncbi.nlm.nih.gov/8772599/
[2] Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535. https://pubmed.ncbi.nlm.nih.gov/1379256/
[3] Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993;388:10-15. https://pubmed.ncbi.nlm.nih.gov/8329825/
[4] Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. https://pubmed.ncbi.nlm.nih.gov/18046908/
[5] Blackman MR. Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time. Ann Intern Med. 2008;149(9):677-9. https://pubmed.ncbi.nlm.nih.gov/18981489/
[6] Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429. (SMART trial, NCT00257712). https://pubmed.ncbi.nlm.nih.gov/22869065/
[7] Quik EH, Valk GD, et al. Reduced growth hormone secretion after cranial irradiation contributes to neurocognitive dysfunction. Growth Horm IGF Res. 2012;22:42-7. https://pubmed.ncbi.nlm.nih.gov/22269954/
[8] Friedman SD, Baker LD, Borson S, et al. Growth hormone-releasing hormone effects on brain gamma-aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA Neurol. 2013;70(7):883-890. https://pubmed.ncbi.nlm.nih.gov/23689947/
[9] Vitiello MV, Moe KE, Merriam GR, et al. Growth hormone releasing hormone improves the cognition of healthy older adults. Neurobiol Aging. 2006;27(2):318-323. https://pubmed.ncbi.nlm.nih.gov/16399214/
[10] Vitiello MV, Moe KE, Merriam GR, et al. Treating age-related changes in somatotrophic hormones, sleep, and cognition. Dialogues Clin Neurosci. 2001;3(3):229-236. https://pubmed.ncbi.nlm.nih.gov/22034239/
[11] Muller EE, Locatelli V, Cocchi D. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998;19(6):717-797. https://pubmed.ncbi.nlm.nih.gov/9861545/
[12] Vance ML, Kaiser DL, Evans WS, et al. The effect of pulsatile administration, continuous infusion, and diurnal variation on the growth hormone (GH) response to GH-releasing hormone in normal men. J Clin Endocrinol Metab. 1986;63(4):872-878. https://pubmed.ncbi.nlm.nih.gov/3091629/
[13] Massoud AF, et al. Growth hormone (GH) autofeedback on GH response to GH-releasing hormone. Role of free fatty acids and somatostatin. J Clin Endocrinol Metab. 1991;72(2):492-499. https://pubmed.ncbi.nlm.nih.gov/1671389/
[14] Granata R, Leone S, Zhang X, Gesmundo I, Steenblock C, Cai R, Sha W, Ghigo E, Hare JM, Bornstein SR, Schally AV. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025. https://pubmed.ncbi.nlm.nih.gov/39537825/
[15] Pedrolli F, Morello G, et al. Growth hormone-releasing hormone attenuates amyloid deposition and neuroinflammation in Alzheimer's disease models. Cell Death Dis. 2026. https://pubmed.ncbi.nlm.nih.gov/41946684/

---

A constructivist reading board for the sermorelin record — every GHRH(1-29) figure logged to its study and the empty long-term adult-evidence members left openly unfilled; sermorelin was a medicine, is read here as research, and nothing on this board is dispensed, prescribed, or sold.